Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
In the 1910s, the American Medical Association fought quackery promoted in pamphlets for drugs and treatments for everything from teething to epilepsy.
AMA J Ethics. 2018;20(11):E1082-1093. doi:
10.1001/amajethics.2018.1082.
Katherine Gentry, MD, MA and Aaron Wightman, MD, MA
A patient’s refusal of tracheostomy during an anticipated difficult intubation prompts critical questions about how to best express respect for a pediatric patient’s autonomy and whether and when deviation from standard of care is clinically and ethically appropriate.
AMA J Ethics. 2018;20(8):E683-689. doi:
10.1001/amajethics.2018.683.
Dr Jamaji C. Nwanaji-Enwerem joins Ethics Talk to discuss his collection of images: Intentionally Retained, Intentionally Fragmented, Accidentally Retained, and Accidentally Fragmented.
Dr Amy B. Cadwallader joins Ethics Talk to discuss her article, coauthored with Kavitha Nallathambi: “How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?”